{{medical}}
{{NoteTA|G1=Chemistry|G2=Medicine}}
{{Drugbox
| verifiedrevid = 460777963
| IUPAC_name = 8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5''H''-benzo[5,6]cyclohepta[1,2-b]pyridine
| image = Desloratadine.svg
| width = 222
| image2 = Desloratadine 3D ball-and-stick.png

<!--Clinical data-->
| tradename = Clarinex (US), Aerius, Dasselta, Deslordis (EU), others
| Drugs.com = {{drugs.com|monograph|desloratadine}}
| MedlinePlus = a602002
| licence_EU = yes
| licence_US = Desloratadine
| pregnancy_AU = B1
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = S2
| legal_UK = POM
| legal_US = Rx-only
| legal_CA = OTC
| legal_status =  
| routes_of_administration = Oral (tablets, solution)

<!--Pharmacokinetic data-->
| bioavailability = Rapidly absorbed
| protein_bound = 83 to 87%
| onset = within 1 hour
| metabolism = [[UGT2B10|UGT2B10]], [[CYP2C8|CYP2C8]]
| metabolites = 3-Hydroxydesloratadine
| duration_of_action = up to 24 hours
| elimination_half-life = 27 hours
| excretion = 40% as conjugated metabolites into urine<br />Similar amount into the feces

<!--Identifiers-->
| IUPHAR_ligand = 7157
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 100643-71-8
| ATC_prefix = R06
| ATC_suffix = AX27
| PubChem = 124087
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00967
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 110575
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FVF865388R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03693
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 291342
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1172

<!--Chemical data-->
| C=19 | H=19 | Cl=1 | N=2
| molecular_weight = 310.82 g/mol
| smiles = Clc4cc2c(C(/c1ncccc1CC2)=C3/CCNCC3)cc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JAUOIFJMECXRGI-UHFFFAOYSA-N
}}

'''地氯雷他定'''（{{lang|en|Desloratadine}}），又稱AERIUS (先靈葆雅)/DENOSIN (美時)，屬於三環長效型的第三代[[抗組織胺|組織胺拮抗劑]](Antagonist)，選擇性作用在H1接受體。接受體結合數據顯示若在濃度2-3ng/ml(7nmol)，與人類組織胺H1接受體會有意義的交互作用。

Desloratadine能抑制組織胺並且會由人類[[肥大細胞|肥大細胞]](mast cell)釋出。

Desloratadine不會通過[[血腦屏障|大腦血管障壁]](blood brain barrier; BBB)。

== 適應症 ==
季節性過敏性鼻炎引起的相關症狀，緩解慢性原發性蕁麻疹相關症狀。

== 注意事項 ==
致癌性、突變性及生殖力損傷。

1. 致癌性：根據 loratadine實驗，給予小鼠(mice) 40 mg/kg/day 18個月的長期實驗，或給予大鼠(rat)實驗上雄性 10 mg/kg/day及雌性 25mg/kg/day 2年的長期實驗，皆有肝細胞腫瘤(合併腺腫瘤及癌)高的發生率；但在長期的臨床實驗上仍未建立。
 
2. 突變性：尚無研究指出本品具有基因突變的危險性。

3. 生殖力損傷：投予雌性大鼠 desloratadine 24mg/kg/day，並不影響生殖力，投予雄性大鼠 12mg/kg/day則會降低精子的活動力及數目，但在 3mg/kg/day下並不影響其生殖力。 

== 參考文獻 ==
*[https://web.archive.org/web/20140106031537/http://www.ccgh.com.tw/ck/ck_medmaintain/download/odeno2..pdf Denosin 停敏 仿單]

{{Antihistamines}}
{{Histaminergics}}

[[Category:苯並環庚三烯並吡啶|Category:苯並環庚三烯並吡啶]]
[[Category:氯代芳烴|Category:氯代芳烴]]
[[Category:H1受體拮抗劑|Y]]
[[Category:外周選擇性藥物|Category:外周選擇性藥物]]
[[Category:哌啶|Category:哌啶]]
[[Category:先靈葆雅|Category:先靈葆雅]]